[go: up one dir, main page]

WO2004015089A3 - Polyionic organic acid formulations - Google Patents

Polyionic organic acid formulations Download PDF

Info

Publication number
WO2004015089A3
WO2004015089A3 PCT/US2003/025419 US0325419W WO2004015089A3 WO 2004015089 A3 WO2004015089 A3 WO 2004015089A3 US 0325419 W US0325419 W US 0325419W WO 2004015089 A3 WO2004015089 A3 WO 2004015089A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
organic acid
polyionic organic
acid formulations
polyionic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/025419
Other languages
French (fr)
Other versions
WO2004015089A2 (en
Inventor
Michael J Bennett
Yen-Ju Chen
Edmund J Niedzinski
Hsien Tseng
Sean Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genteric Inc
Original Assignee
Genteric Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genteric Inc filed Critical Genteric Inc
Priority to AU2003265432A priority Critical patent/AU2003265432A1/en
Publication of WO2004015089A2 publication Critical patent/WO2004015089A2/en
Publication of WO2004015089A3 publication Critical patent/WO2004015089A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a nucleic acid transfection composition comprising a polyionic organic acid and a nucleic acid. Preferably, the polyionic organic acid is a dye. Efficient methods are also provided for administering the compositions, increasing the transfection efficiency in a cell (e.g., secretory gland cell), and using the compositions as nucleic acid stabilizers to prevent in vivo and in vitro nucleic acid degradation, thus increasing the half-life and shelf life of a nucleic acid.
PCT/US2003/025419 2002-08-12 2003-08-12 Polyionic organic acid formulations Ceased WO2004015089A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265432A AU2003265432A1 (en) 2002-08-12 2003-08-12 Polyionic organic acid formulations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40281102P 2002-08-12 2002-08-12
US60/402,811 2002-08-12
US45399903P 2003-03-11 2003-03-11
US60/453,999 2003-03-11
US47614503P 2003-06-04 2003-06-04
US60/476,145 2003-06-04

Publications (2)

Publication Number Publication Date
WO2004015089A2 WO2004015089A2 (en) 2004-02-19
WO2004015089A3 true WO2004015089A3 (en) 2004-07-15

Family

ID=31721505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025419 Ceased WO2004015089A2 (en) 2002-08-12 2003-08-12 Polyionic organic acid formulations

Country Status (2)

Country Link
AU (1) AU2003265432A1 (en)
WO (1) WO2004015089A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888107B2 (en) 2006-07-24 2011-02-15 Nanosphere, Inc. System using self-contained processing module for detecting nucleic acids
US7625746B2 (en) 2006-07-24 2009-12-01 Nanosphere, Inc. Method of denaturing and fragmenting DNA or RNA using ultrasound
CZ301561B6 (en) * 2007-12-04 2010-04-14 Výzkumný ústav živocišné výroby, v. v. i. Pharmaceutical composition to prevent and suppress coccidia
JP7770096B2 (en) 2016-10-14 2025-11-14 ザ チルドレンズ メディカル センター コーポレーション Compositions and methods for treating diseases and disorders of the central nervous system
CA3050690A1 (en) 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosing and treating peroxisomal diseases
US11548936B2 (en) 2017-01-17 2023-01-10 Children's Medical Center Corporation Compositions and methods for treating lysosomal storage diseases and disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932539A (en) * 1996-10-15 1999-08-03 The Board Of Trustees Of The University Of Illinois Biodegradable polymer matrix for tissue repair
US20010036925A1 (en) * 1995-03-24 2001-11-01 Michael German Gene therapy by secretory gland expression
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010036925A1 (en) * 1995-03-24 2001-11-01 Michael German Gene therapy by secretory gland expression
US5932539A (en) * 1996-10-15 1999-08-03 The Board Of Trustees Of The University Of Illinois Biodegradable polymer matrix for tissue repair
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken

Also Published As

Publication number Publication date
WO2004015089A2 (en) 2004-02-19
AU2003265432A8 (en) 2004-02-25
AU2003265432A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2002074969A3 (en) Matrix attachment regions and methods for use thereof
DK0977874T3 (en) Attenuated salmonella strain used as a carrier for oral immunization
AR025683A1 (en) BACILLUS THURINGIENSIS D-ENDOTOXINE COMPOSITIONS ACTIVE AGAINST LEPIDOPTERS AND METHODS OF USE
BRPI0409133A (en) pharmaceutical formulations containing methylnaltrexone
AR023229A1 (en) MUTANT POLYPEPTIDES, AND ITS USE IN DETERGENT COMPOSITIONS.
AU8023898A (en) Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
AU4981101A (en) Subtilisin variants
WO2004038378A3 (en) Phthalocyanine dyes
DK1210411T3 (en) Compositions and Methods for Improved Cell Culture
DE60036537D1 (en) COMPOSITIONS FOR GENETHERAPY OF DIABETES
WO2005016264A3 (en) Diamine derivatives of quinone and uses thereof
DK1675954T3 (en) Nucleic acids useful in triggering tumor cell mortality
WO2005017098A3 (en) AMPHIPATHIC AND POLYCATIONIC COMPOUNDS FOR DELIVERING siRNA
DE502004003219D1 (en) HIGH-BRANCHED POLYCARBONATE AND COPOLYCARBONATE WITH IMPROVED FLUIDITY, THEIR PREPARATION AND USE
WO2004015089A3 (en) Polyionic organic acid formulations
WO2007110628A3 (en) Compositions and methods for therapy of cystic fibrosis
NO20072998L (en) Stabilization of glucocorticoid esters with acids
DK1526840T3 (en) Nanoparticles for DNA administration to a target organ
WO2003070905A3 (en) Electroporation methods for introducing bioactive agents into cells
WO2005079532A3 (en) Methods and compositions for enhancing risc activity in vitro and in vivo
AR017368A1 (en) A PROCEDURE FOR THE INSERTION OF FORANEOUS DNA IN A HOSPEDING CELL, A RECOMBINING VECTOR USED IN THIS PROCEDURE AND THE USE OF THE SAME
HK1040402A1 (en) Compositions and methods using lactadherin or variants thereof
MX2007008980A (en) Nucleic acids for apoptosis of cancer cells.
WO2006055931A3 (en) Vectors for stable gene expression
WO2004071443A3 (en) Methods and compositions for modulating stem cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP